These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 28108630)

  • 1. Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.
    Cullis J; Siolas D; Avanzi A; Barui S; Maitra A; Bar-Sagi D
    Cancer Immunol Res; 2017 Mar; 5(3):182-190. PubMed ID: 28108630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
    Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
    Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
    Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
    Awasthi N; Scire E; Monahan S; Grojean M; Zhang E; Schwarz MA; Schwarz RE
    Oncotarget; 2016 Jul; 7(30):46988-47001. PubMed ID: 27127884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.
    Suenaga M; Yamada S; Fujii T; Tanaka C; Kanda M; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    J Surg Oncol; 2016 Mar; 113(4):413-9. PubMed ID: 27100026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner.
    Wanderley CW; Colón DF; Luiz JPM; Oliveira FF; Viacava PR; Leite CA; Pereira JA; Silva CM; Silva CR; Silva RL; Speck-Hernandez CA; Mota JM; Alves-Filho JC; Lima-Junior RC; Cunha TM; Cunha FQ
    Cancer Res; 2018 Oct; 78(20):5891-5900. PubMed ID: 30104241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model.
    Bressand D; Novell A; Girault A; Raoul W; Fromont-Hankard G; Escoffre JM; Lecomte T; Bouakaz A
    Mol Pharm; 2019 Sep; 16(9):3814-3822. PubMed ID: 31356090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.
    Gao M; Zhang D; Jin Q; Jiang C; Wang C; Li J; Peng F; Huang D; Zhang J; Song S
    Oncotarget; 2016 Sep; 7(36):58133-58141. PubMed ID: 27531898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy.
    Chatterjee M; Ben-Josef E; Robb R; Vedaie M; Seum S; Thirumoorthy K; Palanichamy K; Harbrecht M; Chakravarti A; Williams TM
    Cancer Res; 2017 Nov; 77(21):5925-5937. PubMed ID: 28923854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.
    Kaneda MM; Cappello P; Nguyen AV; Ralainirina N; Hardamon CR; Foubert P; Schmid MC; Sun P; Mose E; Bouvet M; Lowy AM; Valasek MA; Sasik R; Novelli F; Hirsch E; Varner JA
    Cancer Discov; 2016 Aug; 6(8):870-85. PubMed ID: 27179037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
    Camblin AJ; Pace EA; Adams S; Curley MD; Rimkunas V; Nie L; Tan G; Bloom T; Iadevaia S; Baum J; Minx C; Czibere A; Louis CU; Drummond DC; Nielsen UB; Schoeberl B; Pipas JM; Straubinger RM; Askoxylakis V; Lugovskoy AA
    Clin Cancer Res; 2018 Jun; 24(12):2873-2885. PubMed ID: 29549161
    [No Abstract]   [Full Text] [Related]  

  • 12. IL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis.
    Vadevoo SMP; Kang Y; Gunassekaran GR; Lee SM; Park MS; Jo DG; Kim SK; Lee H; Kim WJ; Lee B
    Theranostics; 2024; 14(6):2605-2621. PubMed ID: 38646639
    [No Abstract]   [Full Text] [Related]  

  • 13. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer.
    Neesse A; Michl P; Tuveson DA; Ellenrieder V
    Z Gastroenterol; 2014 Apr; 52(4):360-6. PubMed ID: 24687799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.
    Zhang L; Marrano P; Kumar S; Leadley M; Elias E; Thorner P; Baruchel S
    Clin Cancer Res; 2013 Nov; 19(21):5972-83. PubMed ID: 23989978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.
    Parasido E; Avetian GS; Naeem A; Graham G; Pishvaian M; Glasgow E; Mudambi S; Lee Y; Ihemelandu C; Choudhry M; Peran I; Banerjee PP; Avantaggiati ML; Bryant K; Baldelli E; Pierobon M; Liotta L; Petricoin E; Fricke ST; Sebastian A; Cozzitorto J; Loots GG; Kumar D; Byers S; Londin E; DiFeo A; Narla G; Winter J; Brody JR; Rodriguez O; Albanese C
    Mol Cancer Res; 2019 Sep; 17(9):1815-1827. PubMed ID: 31164413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Schwarz MA; Schwarz RE
    Mol Cancer Ther; 2014 May; 13(5):1032-43. PubMed ID: 24608575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of
    Awasthi N; Schwarz MA; Zhang C; Schwarz RE
    Mol Cancer Ther; 2018 Nov; 17(11):2353-2364. PubMed ID: 30166402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models.
    Li JA; Xu XF; Han X; Fang Y; Shi CY; Jin DY; Lou WH
    Pancreas; 2016 Mar; 45(3):425-33. PubMed ID: 26495780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.
    Zhang C; Awasthi N; Schwarz MA; Hinz S; Schwarz RE
    PLoS One; 2013; 8(2):e58037. PubMed ID: 23460921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
    Neesse A; Frese KK; Chan DS; Bapiro TE; Howat WJ; Richards FM; Ellenrieder V; Jodrell DI; Tuveson DA
    Gut; 2014 Jun; 63(6):974-83. PubMed ID: 24067278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.